Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $2,825 | 3 | 71.8% |
| Unspecified | $950.06 | 7 | 24.1% |
| Food and Beverage | $158.97 | 3 | 4.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Y-mAbs Therapeutics, Inc. | $2,125 | 2 | $0 (2021) |
| GlaxoSmithKline, LLC. | $950.06 | 7 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $765.00 | 2 | $0 (2019) |
| Hoffmann-La Roche Limited | $93.97 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $2,125 | 2 | Y-mAbs Therapeutics, Inc. ($2,125) |
| 2019 | $1,789 | 10 | GlaxoSmithKline, LLC. ($950.06) |
| 2018 | $20.15 | 1 | Hoffmann-La Roche Limited ($20.15) |
All Payment Transactions
13 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/15/2021 | Y-mAbs Therapeutics, Inc. | DANYELZA (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: ONCOLOGY | ||||||
| 06/17/2021 | Y-mAbs Therapeutics, Inc. | DANYELZA (Drug) | Consulting Fee | Cash or cash equivalent | $125.23 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2019 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $496.60 | Research |
| Study: MASTER PROTOCOL TO ASSESS THE SAFETY AND ANTITUMOR ACTIVITY OF GENETIC | ||||||
| 10/10/2019 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $167.63 | Research |
| Study: MASTER PROTOCOL TO ASSESS THE SAFETY AND ANTITUMOR ACTIVITY OF GENETIC | ||||||
| 10/10/2019 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $127.95 | Research |
| Study: MASTER PROTOCOL TO ASSESS THE SAFETY AND ANTITUMOR ACTIVITY OF GENETIC | ||||||
| 10/10/2019 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $89.05 | Research |
| Study: MASTER PROTOCOL TO ASSESS THE SAFETY AND ANTITUMOR ACTIVITY OF GENETIC | ||||||
| 10/10/2019 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $27.01 | Research |
| Study: MASTER PROTOCOL TO ASSESS THE SAFETY AND ANTITUMOR ACTIVITY OF GENETIC | ||||||
| 10/10/2019 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $23.22 | Research |
| Study: MASTER PROTOCOL TO ASSESS THE SAFETY AND ANTITUMOR ACTIVITY OF GENETIC | ||||||
| 10/10/2019 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $18.60 | Research |
| Study: MASTER PROTOCOL TO ASSESS THE SAFETY AND ANTITUMOR ACTIVITY OF GENETIC | ||||||
| 06/02/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $65.00 | General |
| Category: ONCOLOGY | ||||||
| 05/31/2019 | Hoffmann-La Roche Limited | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $73.82 | General |
| Category: None | ||||||
| 03/01/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2018 | Hoffmann-La Roche Limited | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $20.15 | General |
| Category: None | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MASTER PROTOCOL TO ASSESS THE SAFETY AND ANTITUMOR ACTIVITY OF GENETIC | GlaxoSmithKline, LLC. | $950.06 | 7 |
About Ami Desai
Ami Desai is a Pediatric Hematology-Oncology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/28/2007. The National Provider Identifier (NPI) number assigned to this provider is 1790967164.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Ami Desai has received a total of $3,934 in payments from pharmaceutical and medical device companies, with $2,125 received in 2021. These payments were reported across 13 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($2,825).
Practice Information
- Specialty Pediatric Hematology-Oncology
- Location Chicago, IL
- Active Since 11/28/2007
- Last Updated 10/24/2022
- Taxonomy Code 2080P0207X
- Entity Type Individual
- NPI Number 1790967164
Products in Payments
- DANYELZA (Drug) $2,125
- KEYTRUDA (Biological) $765.00
- Non-Covered Product (Drug) $93.97
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Hematology-Oncology Doctors in Chicago
Alexis Thompson, Md, MD
Pediatric Hematology-Oncology — Payments: $1.6M
James Labelle
Pediatric Hematology-Oncology — Payments: $249,251
Sherif Badawy, Md, MD
Pediatric Hematology-Oncology — Payments: $207,866
Dr. Loretta Li, M.d, M.D
Pediatric Hematology-Oncology — Payments: $187,559
Susan Cohn
Pediatric Hematology-Oncology — Payments: $125,685
Leonard Valentino, M.d, M.D
Pediatric Hematology-Oncology — Payments: $117,453